# An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

> **NCT03002376** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** REGN2810

## Key facts

- **NCT ID:** NCT03002376
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-10
- **Primary completion:** 2019-03-05
- **Final completion:** 2020-03-19
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002376, "An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03002376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*